Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Disease-modifying therapies and infectious risks in multiple sclerosis.
CONTINUUM Multiple Sclerosis: Teaching Us About More Than MS and Its ABCs.
Cigarette smoking and the risk of multiple sclerosis: a sibling case-control study in Isfahan, Iran.
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.
Clozapine promotes glycolysis and myelin lipid synthesis in cultured oligodendrocytes.
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
Role of toll-like receptor 2 in ischemic demyelination and oligodendrocyte death.
Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis.
2nd International Symposium on Gait and Balance in Multiple Sclerosis: interventions for gait and balance in MS.
NDRG2 promoted secreted miR-375 in microvesicles shed from M1 microglia, which induced neuron damage.
Duloxetine for the Treatment of Overactive Bladder Syndrome in Multiple Sclerosis: A Pilot Study.
A single session of 1 mA anodal tDCS-supported motor training does not improve motor performance in patients with multiple sclerosis.
Objective and subjective measures reflect different aspects of balance in multiple sclerosis.
Retrieval practice is a robust memory aid for memory-impaired patients with MS.
Multiple sclerosis-like neurological manifestations in a coeliac patient: nothing is as it seems.
Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients.
Multiple sclerosis genetics.
Multiple sclerosis and infections.
Gatekeeper role of brain antigen-presenting CD11c+ cells in neuroinflammation.
Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis?
Progression and CSF Inflammation after Eradication of Oligoclonal Bands in an MS Patient Treated with Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma.
"Liberation treatment" for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free.
N-Cadherin Promotes Recruitment and Migration of Neural Progenitor Cells from the SVZ Neural Stem Cell Niche into Demyelinated Lesions.
The Fc Receptor-Like 3 Polymorphisms (rs7528684, rs945635, rs3761959 and rs2282284) and The Risk of Neuromyelitis Optica in A Chinese Population.
Pages
« first
‹ previous
…
342
343
344
345
346
347
348
349
350
…
next ›
last »